Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Aizawa, Junichi ^a,b   Sakayama, Kenshi ^a   Kamei, Setsuya ^a,b   Kidani, Teruki ^a   Yamamoto, Haruyasu ^a   Norimatsu, Yoshiaki ^b   Masuno, Hiroshi ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BROXURIDINE; CD34 ANTIGEN; DNA; GELATINASE A; MATRIGEL; PROTEIN KINASE B; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CELL ASSAY; CELL CULTURE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; HUMAN; LUNG TUMOR; METASTASIS; MICROCIRCULATION; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD34; CELL LINE, TUMOR; CHROMANS; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROCIRCULATION; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77649290013     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-51     Document Type: Article

References (38)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839. 10.1016/0092-8674(95)90199-X, 8521507.
2. Lemberger T, Desvergne B, Wahli W. Peroxisome prolifarator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996, 12:335-363. 10.1146/annurev.cellbio.12.1.335, 8970730.
3. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996, 87:377-389. 10.1016/S0092-8674(00)81359-8, 8898192.
4. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA, He T-C. Nuclear receptor agonist as potent differentiation therapy agents for human osteosarcoma. Clin Cancer Res 2002, 8:1288-1294.
5. Lucarelli E, Sangiorgi L, Maini V, Lattanzi G, Marmiroli S, Reggiani M, Mordenti M, Gobbi GA, Scrimieri F, Bertoja AZ, Picci P. Troglitazione affects survival of human osteosarcoma cells. Int J Cancer 2002, 98:344-351. 10.1002/ijc.10203, 11920584.
6. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95:8806-8811. 10.1073/pnas.95.15.8806, 21158, 9671760.
7. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003, 9:1-9.
8. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006, 6:53. 10.1186/1471-2407-6-53, 1450298, 16519808.
9. Magenta G, Borenstein X, Rolando R, Jasnis MA. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer 2008, 8:47. 10.1186/1471-2407-8-47, 2268944, 18261208.
10. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999, 16:179-192. 10.1046/j.1464-5491.1999.00023.x, 10227562.
11. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001, 19:292-315. 10.1081/CNV-100102557, 11338887.
12. Matrisian LM. Cancer Biology: extracellular proteinases in malignancy. Curr Biol 1999, 9:R776-R778. 10.1016/S0960-9822(00)80011-1, 10531025.
13. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999, 43(Suppl):S42-S51. 10.1007/s002800051097, 10357558.
14. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000, 6:572-577.
15. Yang S-Y, Yu H, Krygier JE, Wooley PH, Mott MP. High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma 2007, 2007:95628. 10.1155/2007/95628, 2225469, 18274612.
16. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998, 76:418-422. 10.1002/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.0.CO;2-5, 9579581.
17. Kamei S, Sakayama K, Tamashiro S, Aizawa J, Miyawaki J, Miyazaki T, Yamamoto H, Norimatsu Y, Masuno H. Ketoprofen in topical formulation decreases the matrix metalloproteinase-2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma. J Orthop Res 2009, 27:909-915. 10.1002/jor.20832, 19105229.
18. Fukaya Y, Ishiguro N, Senga T, Ichigotani Y, Sohara Y, Tsutsui M, Shioura T, Iwamoto T, Hamaguchi M. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep 2005, 14:847-852.
19. Hinegardner RT. An improved fluorometric assay for DNA. Anal Biochem 1971, 39:197-201. 10.1016/0003-2697(71)90476-3, 5544593.
20. Masuno H, Okamoto S, Iwanami J, Honda K, Shiosaka T, Kidani T, Sakayama K, Yamamoto H. Effect of 4-nonylphenol on cell proliferation and adipocyte formation in cultures of fully differentiated 3T3-L1 cells. Toxicol Sci 2003, 75:314-320. 10.1093/toxsci/kfg203, 12883076.
21. Masuno H, Iwanami J, Kidani T, Sakayama K, Honda K. Bisphenol A accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci 2005, 84:319-327. 10.1093/toxsci/kfi088, 15659569.
22. Schaefer KL, Takahashi H, Morales VM, Harris G, Barton S, Osawa E, Nakajima A, Saubermann LJ. PPARγ inhibitors reduce tubulin protein levels by a PPARγ, PPARδ and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int J Cancer 2007, 120:702-713. 10.1002/ijc.22361, 17096328.
23. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 1985, 82:3262-3266. 10.1073/pnas.82.10.3262, 397755, 2860667.
24. Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987, 111:841-845.
25. Sakayama K, Kidani T, Miyazaki T, Shirakata H, Kimura Y, Kamogawa J, Masuno H, Yamamoto H. Effect of ketoprofen in topical formulation on vascular endothelial growth factor expression and tumor growth in nude mice with osteosarcoma. J Orthop Res 2004, 22:1168-1174. 10.1016/j.orthres.2004.03.015, 15475193.
26. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Östör AG, Nie G, Lopata A, Salamonsen LA. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002, 94:1466-1475. 10.1002/cncr.10355, 11920503.
27. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844. 10.1038/362841a0, 7683111.
28. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferators-activated receptor gamma-independent mechanism in breast cancer-derived cell line. Clin Cancer Res 2004, 10:7022-7030. 10.1158/1078-0432.CCR-04-0879, 15501982.
29. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br J Pharmacol 2004, 143:933-937. 10.1038/sj.bjp.0705973, 1575954, 15533890.
30. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003, 63:2172-2178.
31. Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001, 61:589-593.
32. Yang Y-C, Ho T-C, Chen S-L, Lai H-Y, Wu J-Y, Tsao Y-P. Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. BMC Cancer 2007, 7:216. 10.1186/1471-2407-7-216, 2233635, 18021457.
33. Park BK, Zeng X, Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 2001, 61:7647-7653.
34. Zhang Y, Thant AA, Hiraiwa Y, Naito Y, Sein TT, Sohara Y, Matsuda S, Hamaguchi M. A role for focal adhesion kinase in hyaluronan-dependent MMP-2 secretion in a human small-cell lung carcinoma cell line, QC90. Biochem Biophys Res Commun 2002, 290:1123-1127. 10.1006/bbrc.2001.6321, 11798192.
35. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996, 32A:2474-2484. 10.1016/S0959-8049(96)00379-6, 9059336.
36. Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, He QY, Cheung AL. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/Akt signaling pathway. Int J Cancer 2009, 125:2576-2585. 10.1002/ijc.24675, 19551863.
37. Teranishi F, Takahashi N, Gao N, Akamo Y, Takeyama H, Manabe T, Okamoto T. Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci 2009, 100:770-777. 10.1111/j.1349-7006.2009.01084.x, 19469020.
38. Meteoglu I, Meydan N, Erkus M. Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy. J Exp Clin Cancer Res 2008, 27:69. 10.1186/1756-9966-27-69, 2588562, 19014499.